CHRS, US19249H1032

Coherus Oncology stock marks its October 7 CVR distribution

Published on 10/07/2026 at 00:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coherus Oncology stock posted Q2 2026 revenue of USD 14.31 million, up 39.53 percent year over year. Zacks lists four analyst targets averaging USD 7.75.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology stock (ISIN US19249H1032) was last at USD 1.03 on Nasdaq on October 6, 2026, down 8.04 percent from the prior close of USD 1.12. The company reaches a key shareholder date on October 7, 2026, when contingent value rights tied to its legacy biosimilar assets are scheduled for distribution.

CVR distribution reaches shareholders

According to Coherus Oncology in its September 23, 2026 release, the company began marketing its remaining legacy biosimilar assets and retained Oppenheimer as financial adviser. The package includes patents, intellectual property, royalties, cell lines and related regulatory materials.

Shareholders of record on September 30, 2026 are eligible for the CVRs, according to Nasdaq. The rights provide a pro rata claim on cash or other consideration received from asset sales or licensing fees, making the distribution date important while the sale process develops.

Revenue grows as losses persist

Yahoo Finance reports Q2 2026 revenue of USD 14.31 million and GAAP earnings per share of USD -0.19, compared with a consensus estimate of USD -0.12. Revenue therefore rose 39.53 percent from the same quarter a year earlier, but the earnings figure remained below the published estimate.

The operating picture is increasingly concentrated around LOQTORZI, the approved PD-1 inhibitor, while Tagmokitug and Casdozokitug remain mid-stage development programs. The company describes this mix in its September 23, 2026 release, linking future value to commercial execution, clinical data and potential licensing transactions.

Analyst targets remain far above Nasdaq price

Zacks lists an average price target of USD 7.75 from four analysts, with a low of USD 4.00 and a high of USD 10.00. Its average brokerage recommendation is 1.57 from seven firms, a scale result between Strong Buy and Hold.

That analyst spread puts the CVR process and upcoming oncology data in a sharper valuation context. The September 23 release also states that proceeds from the legacy asset sale may be limited, so the rights do not represent a fixed cash payment.

CHRS trades near its 52-week low

At USD 1.03 on October 6, 2026, CHRS traded USD 0.02 above its 52-week low of USD 1.01 and USD 1.59 below its 52-week high of USD 2.62. The market capitalization was USD 159.1 million, with volume of 2,952,869 shares on Nasdaq.